


NKY80

Chemical Properties

CAS No. : 299442-43-6
 Formula: C₁₂H₁₁N₃O₂
 Molecular Weight: 229.23
 Storage: Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Actual storage temperature shall be subject to the COA.



Biological Description

| | |
|----------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Description | NKY80 regulates the adenylyl cyclase catalytic activity in heart and lung tissues. NKY80 is a non-competitive inhibitor of adenylyl cyclase type V isoform (IC ₅₀ s: 8.3 μM, 132 μM, and 1.7 mM for type V, III and II, respectively). |
| Targets(IC ₅₀) | Adenylate cyclase |
| In vitro | NKY80 (20 μM) blocks the increase in LVP and ventricular cAMP levels[2]. NKY80 (20 μM; 2 hours) completely blocks the elevations in both cAMP content and renin release from isolated JG cells[3]. |

Solubility Information

| | |
|---------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Solubility | DMSO: 225 mg/mL (981.55 mM),Sonication is recommended. (< 1 mg/ml refers to the product slightly soluble or insoluble) |
| In vivo Formulation | 10% DMSO+40% PEG300+5% Tween 80+45% Saline: 5 mg/mL (21.81 mM),Sonication is recommended. <i>Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions.</i> |

Preparing Stock Solutions

| | 1mg | 5mg | 10mg |
|-------|-----------|------------|------------|
| 1 mM | 4.3624 mL | 21.8122 mL | 43.6243 mL |
| 5 mM | 0.8725 mL | 4.3624 mL | 8.7249 mL |
| 10 mM | 0.4362 mL | 2.1812 mL | 4.3624 mL |
| 50 mM | 0.0872 mL | 0.4362 mL | 0.8725 mL |

Please select the appropriate solvent to prepare the stock solution, according to the solubility of the product in different solvents. Please use it as soon as possible.

Note: The dilution table applies only to solid products. For liquid products, please calculate the stock solution based on the stated concentration and/or density.

Reference

Onda T, et al. Type-specific regulation of adenylyl cyclase. Selective pharmacological stimulation and inhibition of adenylyl cyclase isoforms. *Biol Chem.* 2001 Dec 21;276(51):47785-93.

Harney JA, et al. Insulin-like stimulation of cardiac fuel metabolism by physiological levels of glucagon: involvement of PI3K but not cAMP. *Am J Physiol Endocrinol Metab.* 2008 Jul;295(1):E155-61.

Ortiz-Capisano MC, et al. Adenylyl cyclase isoform v mediates renin release from juxtaglomerular cells. *Hypertension.* 2007 Mar;49(3):618-24.

Inhibitor · Natural Compounds · Compound Libraries · Recombinant Proteins

This product is for Research Use Only · Not for Human or Veterinary or Therapeutic Use

Tel: 781-999-4286 E_mail: info@targetmol.com Address: 34 Washington Street, Wellesley Hills, MA 02481